Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2006 Sep;67(5):321–333. doi: 10.1016/j.curtheres.2006.10.002

Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study

Gloria Lena Vega 1,2,*, Monohar Vajja 1, Natalia Palacio 1, Nilo B CaterP 1,2, Scott M Grundy 1,2
PMCID: PMC3965981  PMID: 24678105

Abstract

Background:

Plasma lipid abnormalities commonly persist in patients with diabetic dyslipidemia in spite of statin monotherapy.

Objective:

The aim of this study was to determine whether fenofibrate plus low-dose nicotinic acid adequately improves the lipoprotein profile in patients with diabetic dyslipidemia who are being treated with a statin.

Methods:

In this open-label, crossover study, patients with type 2 diabetes mellitus who were receiving statin treatment were enrolled at the Lipid Clinic of the Veterans Affairs Medical Center, Dallas, Texas, and administered simvastatin 20 mg/d for 8 weeks. At the end of the 8-week period, fenofibrate 160 mg/d was added for 8 weeks, followed by the addition of extended-release nicotinic acid 1 g/d for an additional 8 weeks. The first subject was recruited on September 25, 2003, and the last subject was recruited on September 28, 2004. Liver function tests, creatine phosphokinase activity, and blood glucose levels were assessed every 4 weeks to assess tolerability. Levels of fasting plasma lipids and lipoprotein cholesterol were measured every 8 weeks on 3 consecutive days in each patient; C-reactive protein, lipoprotein pattern, and glycosylated hemoglobin levels were assessed once every 8 weeks. Plasma levels of total cholesterol, triglycerides, very-low-density lipoprotein plus intermediate-density lipoprotein cholesterol (VLDL+IDL-C), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B were also measured.

Results:

Twenty-six patients were enrolled in the study and 20 patients (18 men, 2 women; mean [SD] age, 58.8 [6.5] years) completed it. The mean plasma triglyceride level was significantly decreased (−29.2%; P= 0.004) and the mean HDL-C level was significantly increased (+13.5%; P < 0.001) with 3-drug treatment (simvastatin + fenofibrate + extended-release nicotinic acid) compared with simvastatin monotherapy. Significant reductions in plasma levels of VLDL+IDL-C (−35.7%; P = 0.001), VLDL+IDL-apolipoprotein B (−30%; P = 0.005), non-HDL-C (−12.9%; P = 0.001), and total-apolipoprotein B (−17.9%; P < 0.001) were seen with the 3-drug treatment compared with simvastatin alone. Compared with simvastatin monotherapy, simvastatin + fenofibrate-treated (2-drug treatment) patients had significantly lower plasma levels of triglycerides (−24.9%; P = 0.014) and significantly higher levels of HDL-C (+5.4%; P = 0.008). Significant reductions were also seen in levels of VLDL+IDL-C (−28.6%; P = 0.004), VLDL+IDL-apolipoprotein B (−26.7%; P < 0.001), non-HDL-C (−9.1 %; P= 0.004), and total-apolipoprotein B (−12.3%; P < 0.001) in the 2-drug treatment group compared with the simvastatin monotherapy group. The administration of 3-drug treatment was associated with improved responses in all lipoprotein fractions, although only the increase in HDL-C level was statistically significant (+7.7%; P = 0.008) compared with 2-drug treatment.

Conclusions:

Treatment with the 3-drug regimen was associated with a significant reduction in triglyceride levels compared with simvastatin monotherapy. However, there was not a significant incremental reduction in triglyceride levels when nicotinic acid was added to the 2-drug treatment, suggesting that the triglyceride-lowering effect of fenofibrate + nicotinic acid is not cumulative. To obtain clinically meaningful responses, particularly for the treatment of elevated HDL-C, higher doses of nicotinic acid might be required.

Key words: fenofibrate, type 2 diabetes, dyslipidemia, nicotinic acid

Full Text

The Full Text of this article is available as a PDF (771.4 KB).

References

  • 1.Juutilainen A., Lehto S., Ronnemaa T. Type 2 diabetes as a “coronary heart disease equivalent”: An 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28:2901–2907. doi: 10.2337/diacare.28.12.2901. [DOI] [PubMed] [Google Scholar]
  • 2.Goldberg R.B., Mellies M.J., Sacks F.M., Care Investigators Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998;98:2513–2519. doi: 10.1161/01.cir.98.23.2513. [DOI] [PubMed] [Google Scholar]
  • 3.Pyorala K., Pedersen T.R., Kjekshus J. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. 1997;20:614–620. doi: 10.2337/diacare.20.4.614. [published correction appears in Diabetes Care. 1997;20:1048] [DOI] [PubMed] [Google Scholar]
  • 4.Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7–22. [Google Scholar]
  • 5.Colhoun H.M., Betteridge D.J., Durrington P.N., CARDS Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696. doi: 10.1016/S0140-6736(04)16895-5. [DOI] [PubMed] [Google Scholar]
  • 6.Garg A., Grundy S.M. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318:81–86. doi: 10.1056/NEJM198801143180204. [DOI] [PubMed] [Google Scholar]
  • 7.Grundy S.M., Vega G.L., Yuan Z. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial) Am J Cardiol. 2005;95:462–468. doi: 10.1016/j.amjcard.2004.10.012. [published correction appears in Am J Cardiol. 2006;98:427–428] [DOI] [PubMed] [Google Scholar]
  • 8.Garg A., Grundy S.M. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes. 1989;38:364–372. doi: 10.2337/diab.38.3.364. [published correction appears in Diabetes. 1990;39:1313] [DOI] [PubMed] [Google Scholar]
  • 9.Allemann S., Diem P., Egger M. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: Meta-analysis of randomised controlled trials. Curr Med Res Opin. 2006;22:617–623. doi: 10.1185/030079906X89865. [DOI] [PubMed] [Google Scholar]
  • 10.Garg A., Grundy S.M. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264:723–726. [PubMed] [Google Scholar]
  • 11.Elam M.B., Hunninghake D.B., Davis K.B. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000;284:1263–1270. doi: 10.1001/jama.284.10.1263. [DOI] [PubMed] [Google Scholar]
  • 12.Grundy S.M., Vega G.L., McGovern M.E., Diabetes Multicenter Research Group Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162:1568–1576. doi: 10.1001/archinte.162.14.1568. [DOI] [PubMed] [Google Scholar]
  • 13.Koskinen P., Manttari M., Manninen V. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820–825. doi: 10.2337/diacare.15.7.820. [DOI] [PubMed] [Google Scholar]
  • 14.Rubins H.B., Robins S.J., Collins D. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT) Arch Intern Med. 2002;162:2597–2604. doi: 10.1001/archinte.162.22.2597. [DOI] [PubMed] [Google Scholar]
  • 15.Robins S.J., Rubins H.B., Faas F.H., Veterans Affairs HDL Intervention Trial (VA-HIT) Insulin resistance and cardiovascular events with low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) Diabetes Care. 2003;26:1513–1517. doi: 10.2337/diacare.26.5.1513. [DOI] [PubMed] [Google Scholar]
  • 16.Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–910. [published correction appears in Lancet. 2001;357:1890] [PubMed] [Google Scholar]
  • 17.Keech A., Simes R.J., Barter P., FIELD Study Investigators Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005;366:1849–1861. doi: 10.1016/S0140-6736(05)67667-2. [DOI] [PubMed] [Google Scholar]
  • 18.Chang J.T., Staffa J.A., Parks M., Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004;13:417–426. doi: 10.1002/pds.977. [DOI] [PubMed] [Google Scholar]
  • 19.Jones P.H., Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120–122. doi: 10.1016/j.amjcard.2004.08.076. [DOI] [PubMed] [Google Scholar]
  • 20.Capuzzi D.M., Guyton J.R., Morgan J.M. Efficacy and safety of an extended-release niacin (niaspan): A long-term study. Am J Cardiol. 1998;82:740–810. doi: 10.1016/s0002-9149(98)00731-0. discussion 85U86U. [DOI] [PubMed] [Google Scholar]
  • 21.Guyton J.R., Blazing M.A., Hagar J., Niaspan-Gemfibrozil Study Group Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160:1177–1184. doi: 10.1001/archinte.160.8.1177. [DOI] [PubMed] [Google Scholar]
  • 22.Canner P.L., Furberg C.D., Terrin M.L., McGovern M.E. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol. 2005;95:254–257. doi: 10.1016/j.amjcard.2004.09.013. [DOI] [PubMed] [Google Scholar]
  • 23.Canner P.L., Furberg C.D., McGovern M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol. 2006;97:477–479. doi: 10.1016/j.amjcard.2005.08.070. [DOI] [PubMed] [Google Scholar]
  • 24.Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405–418. doi: 10.1111/j.0954-6820.1988.tb15891.x. [DOI] [PubMed] [Google Scholar]
  • 25.American Diabetes Association Clinical practice recommendations 2005. Diabetes Care. 2005;28(Suppl 1):S1–S79. doi: 10.2337/diacare.28.suppl_1.s1. [DOI] [PubMed] [Google Scholar]
  • 26.Grundy S.M., Cleeman J.I., Daniels S.R., American Heart Association, and the National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404. [published corrections appear in Circulation. 2005;112:e297 and Circulation. 2005;112:e298] [DOI] [PubMed] [Google Scholar]
  • 27.World Medical Association Declaration of Helsinki . WMA; Ferney-Voltaire, France: 1989. Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects [WMA Web site]http://www.wma.net Available at: Accessed October 7, 2006. [Google Scholar]
  • 28.European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization . WHO; Geneva, Switzerland: 2002. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6.http://www.emea.eu.int Available at: Accessed October 7, 2006. [Google Scholar]
  • 29.Vega G.L., Grundy S.M. Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia. JAMA. 1989;262:3148–3153. [PubMed] [Google Scholar]
  • 30.Austin M.A., Hokanson J.E. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. Med Clin North Am. 1994;78:99–115. doi: 10.1016/s0025-7125(16)30178-x. [DOI] [PubMed] [Google Scholar]
  • 31.Prisant L.M. Clinical trials and lipid guidelines for type II diabetes. J Clin Pharmacol. 2004;44:423–430. doi: 10.1177/0091270004263016. [DOI] [PubMed] [Google Scholar]
  • 32.Robins S.J., Bloomfield H.E. Fibric acid derivatives in cardiovascular disease prevention: Results from the large clinical trials. Curr Opin Lipidol. 2006;17:431–439. doi: 10.1097/01.mol.0000236370.27508.9d. [DOI] [PubMed] [Google Scholar]
  • 33.Brown B.G., Zhao X.Q., Chait A. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592. doi: 10.1056/NEJMoa011090. [DOI] [PubMed] [Google Scholar]
  • 34.Taylor A.J., Sullenberger L.E., Lee H.J. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebocontrolled study of extended-release niacin on atherosclerosis progression in sec ondary prevention patients treated with statins. Circulation. 2004;110:3512–3517. doi: 10.1161/01.CIR.0000148955.19792.8D. [published corrections appear in Circulation. 2004;110:3615 and Circulation. 2005;111:e446] [DOI] [PubMed] [Google Scholar]
  • 35.Birjmohun R.S., Hutten B.A., Kastelein J.J., Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185–197. doi: 10.1016/j.jacc.2004.10.031. [DOI] [PubMed] [Google Scholar]
  • 36.National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421. [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES